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NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER
The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell
Lung Cancer and Other Thoracic Malignancies
Petros Nikolinakos, MD,* and John V. Heymach, MD, PhD*†
Cediranib (AZD2171; Recentin, AstraZeneca, Wilmington, Dela-
ware) is a once-daily oral tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptors 1, 2, and 3, c-KIT, and
platelet-derived growth factor receptors. In preclinical testing it
inhibits tumor angiogenesis and inhibits tumor growth in a wide
range of tumor models. Phase 1 studies show cediranib to be
generally well tolerated as monotherapy at doses of 45 mg/d or less,
with a pharmacokinetic profile that supports once-daily oral admin-
istration and toxic effects consistent with those seen in other agents
that target the vascular endothelial growth factor pathway. Encour-
aging results from phase 1 studies as monotherapy or in combination
with chemotherapy have prompted further investigation in several
thoracic malignancies, including ongoing trials in malignant me-
sothelioma, small cell lung cancer, and an ongoing phase 2/3 trial in
non-small cell lung cancer (NSCLC) in combination with chemo-
therapy. The NSCLC trials include patients with squamous cell
histologic features and treated brain metastases, populations for
which bevacizumab is currently not indicated. These trials will
determine whether cediranib will join the growing armamentarium
of therapeutic options for thoracic malignancies and broaden the
number of patients with NSCLC who could potentially benefit from
antiangiogenic therapy.
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Lung cancer is the leading cause of cancer deaths world-wide.1 Approximately 85% of lung cancers are non-small
cell lung cancer (NSCLC), most of which are diagnosed with
advanced or metastatic disease. Platinum-based doublet che-
motherapy remains the current standard first-line treatment
for these patients, with no significant differences in efficacy
observed among four different regimens.2 In the Eastern
Cooperative Oncology Group 4599 trial, which studied pa-
tients with nonsquamous histologic features and no history of
brain metastases, the addition of bevacizumab to chemother-
apy was found to prolong survival by 2 to 12.3 months
compared with chemotherapy alone.3
Small cell lung cancer (SCLC) is a biologically distinct
entity and further distinguished from NSCLC by its rapid
doubling time, high growth fraction, and early and wide-
spread metastasis. Similar to NSCLC, however, patients with
SCLC typically present with metastatic or extensive-stage
disease. The overall survival of patients with SCLC remains
less than 1 year and has not changed substantially during the
past three decades.
Clearly, new therapeutic approaches are needed for both
NSCLC and SCLC, and a growing number of new therapeutic
agents are under investigation. The results of Eastern Coopera-
tive Oncology Group 4599 have validated the vascular endothe-
lial growth factor (VEGF) pathway as a therapeutic target for
selected patients with NSCLC. Cediranib is one of a growing list
of potent, oral tyrosine kinase inhibitors (TKIs) that inhibit the
VEGF pathway that have demonstrated promising clinical ac-
tivity and are undergoing evaluation for lung cancer and other
thoracic malignancies.4
TUMOR ANGIOGENESIS
Tumor growth and metastatic spread are known to be
angiogenesis dependent.5 Although a large number of factors
are known to play a role in angiogenesis, VEGF (also known
as VEGF-A) seems to play a central role for many tumors.6
The production of VEGF can be markedly up-regulated in
tumors by oncogene activation,7 loss of tumor suppressor
function,8 or changes in oxygen or glucose status.9 VEGF
binds to Flt-1 (VEGFR-1) and KDR (VEGFR-2) transmem-
brane receptor kinases. Receptor activation leads to several
key processes of the angiogenic cascade, including enhanced
vascular permeability, capillary tube formation, neovascular
survival and endothelial cell migration, proliferation, and
protease expression.10 These effects were previously thought
to be regulated primarily by VEGFR-2, although recent
studies have demonstrated the importance of VEGFR-1 in
tumor angiogenesis.11 VEGFR-3, which binds VEGF-C and
VEGF-D, seems to play a prominent role in lymphatic vessel
formation.12,13
VEGF is overexpressed in both NSCLC and SCLC, and
elevated levels of tumor or serum VEGF have been found to
be a negative prognostic factor.14–18 c-KIT and platelet-
derived growth factor receptor (PDGFR) are also commonly
Departments of *Thoracic/Head and Neck Medical Oncology and †Cancer
Biology, University of Texas MD Anderson Cancer Center, Houston,
Texas.
Disclosure: Dr. Heymach has received research support and an honorarium to
serve on a Scientific Advisory Committee for AstraZeneca Pharmaceuticals.
Address for correspondence: John V. Heymach, MD, PhD, Department of
Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer
Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030-4009.
E-mail: jheymach@mdanderson.org
Copyright © 2008 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/08/0306-0131
Journal of Thoracic Oncology • Vol. 3, No. 6, Supplement 2, June 2008 S131
overexpressed in SCLC,19,20 but thus far an inhibitor of these
pathways, imatinib, has not demonstrated significant benefit
as monotherapy or in combination with chemotherapy.21–23
TARGETING THE VEGF PATHWAY WITH TKIS
AND ANTIBODIES
Approaches to targeting the VEGF pathway include
antibodies or other proteins that bind the VEGF ligand (i.e.,
bevacizumab, VEGF-trap), antibodies or antibody fragments
directed against the VEGFRs themselves (i.e., CDP-791), or
small-molecule VEGFR tyrosine kinase inhibitors (RTKIs).
Most new agents that target VEGF currently in development
are RTKIs. Because these agents typically interact with the
adenosine triphosphate binding pocket, which is highly con-
served among tyrosine kinases, these drugs typically inhibit
multiple RTKIs. RTKIs are distinguished from one another
mainly by their spectrum of activity, potency of target inhi-
bition, and pharmacokinetic properties.
They have several potential advantages and disadvan-
tages compared with antibodies or other proteins: they are
typically oral instead of intravenously administered; they
usually have a shorter half-life (i.e., hours or days versus
weeks), which may provide useful in managing toxic effects,
and they may target several therapeutically relevant pathways
simultaneously (i.e., VEGFRs, PDGFR, and c-KIT). Proteins
typically provide greater specificity, which helps minimize
toxic effects from off-target effects (i.e., imatinib-induced
cardiomyopathy from Abl inhibition24), and have a longer
half-life, which may be important if sustained inhibition is
critical.
A growing number of RTKIs that target the VEGF path-
way are being tested in lung cancer.4,25 These agents include
vandetanib (targetingVEGFR2, RET, and epidermal growth factor
receptor),26 sorafenib (VEGFR-2, -3, PDGFR-, Raf-1),27,28
sunitinib (VEGFR-1, -2, and -3, PDGFR, c-KIT, Flt-3),29 ax-
itinib (VEGFR-1, -2, and -3, PDGFR, c-KIT), pazopanib (tar-
geting VEGFR-1, -2, and -3, PDGFR, and c-KIT), AMG706,
and cediranib.30 We focus herein on cediranib.
PRECLINICAL STUDIES OF CEDIRANIB
Based on in vitro studies, cediranib potently inhibits
VEGFR-1, -2, and -3 recombinant kinases with inhibitor
concentration at 50% (IC50) values of 5, less than 1, and less
than 3 nanomoles, respectively. It also inhibits PDGFR- and
c-Kit human recombinant tyrosine kinase with IC50 values of
2 and 5 nanomoles, respectively.31 These concentrations are
well below plasma levels of the drug that can be sustained in
patients in phase 1 clinical studies.
In vivo, cediranib (0.75–6 mg/kg daily) inhibits the
growth of a wide range of tumor xenografts in a dose-dependent
manner after continuous once-daily oral administration. Histo-
logic analysis of Calu-6 lung tumors treated with cediranib
revealed a reduction in microvessel density and an increase in
vessel pruning mostly at the periphery of tumors. VEGF-driven
phosphorylation of KDR was also reduced correlating with a
reduction in microvessel density.31,32
CLINICAL STUDIES OF CEDIRANIB
In the first phase 1 study conducted in patients with
advanced solid tumors, 36 patients were evaluated in a
standard dose escalation scheme at doses of 0.5 to 60 mg,
given orally daily. Cediranib had a half-life of approximately
22 hours, supporting a once-daily dosing regimen. It is
well-tolerated at 45 mg or less, with common adverse effects
of fatigue, nausea, diarrhea, and vomiting. In the randomized
phase portion of the study, an additional 47 patients were
enrolled at 20, 30, or 45 mg orally daily. Six patients had
NSCLC. The major toxic effects included hypertension, di-
arrhea, and voice hoarseness. Of the 83 patients enrolled, two
had a partial response, one in prostate, and one in renal
cancer. Stable disease was seen in 22 patients, including three
who had lung cancer. Dynamic contrast-enhanced magnetic
resonance imaging revealed a significant reduction in tumor
blood flow and vascular permeability in patients treated with
cediranib.33 In addition, soluble VEGFR-2 levels showed
dose- and time-dependent decreases at doses of 20 mg and
TABLE 1. Selected Trials With Cediranib in Thoracic Malignancies
Disease Regimen Phase Sponsor Status
First-line advanced
NSCLC
PC and cediranib I NCIC Completed35
PC and cediranib or placebo Randomized phase II/III NCIC Ongoing
GC and cediranib Phase I NCIC Completed36
GCarbo and with cediranib
or placebo
Randomized phase II NCCTG, NCI Ongoing
Previously treated
NSCLC or HNC
Cediranib I AZ Ongoing
Previously treated
NSCLC
Pem and cediranib II NCI Ongoing
First-line extensive
SCLC, neuroendocrine
EP and cediranib I Astra-Zeneca Ongoing
Recurrent SCLC Cediranib II NCI Ongoing
Malignant
mesothelioma
Cediranib II NCI Ongoing
EP, etoposide and cisplatin; GC, gemcitabine and cisplatin; GCarbo, gemcitabine and carboplatin; HNC, head and neck cancer; NCIC, National Cancer Institute of Canada;
NSCLC, non-small cell lung cancer; NCCTG, North Central Cancer Treatment Group; NCI, National Cancer Institute; PC, paclitaxel and carboplatin; SCLC, small cell lung cancer.
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lower, indicating target inhibition, which is consistent with
other agents that target the VEGFR pathway, such as
sunitinib.34
A subsequent phase 1 study investigated the role of
cediranib in combination with carboplatin and paclitaxel in
patients with advanced NSCLC (Table 1). Patients with squa-
mous cell histologic findings and treated, stable brain metas-
tasis were permitted in the study. Hypertension was the most
common adverse effect seen in six patients and was success-
fully managed. Toxic effects overall seemed manageable and
predictable. Of the 15 patients who were evaluable for re-
sponse, six had a partial response, eight had stable disease,
and one had partial disease. Many patients with stable disease
had evidence of tumor shrinkage, including central cavita-
tion.35 Based on these encouraging results, a randomized,
double-blinded, phase 2/3 trial of carboplatin and paclitaxel
with cediranib versus placebo in patients with advanced or
metastatic NSCLC is currently under way (National Cancer
Institute of Canada CTG BR.24).
Cediranib was subsequently tested in combination with
cisplatin and gemcitabine as first-line therapy for advanced
NSCLC.36 Adverse events included hypertension, fatigue,
and diarrhea, and a patient experienced reversible central
nervous system ischemia. The 30-mg dose was believed to be
better tolerated than 45 mg in this regimen and was the
recommended dose for future study. The preliminary analysis
suggests that the regimen has significant antitumor activity. A
phase 2 study of gemcitabine with carboplatin is also ongoing.
Cediranib is also being investigated for SCLC. Cediranib
monotherapy is undergoing phase 2 testing in patients with
recurrent SCLC after the failure of first-line chemotherapy. A
trial of cediranib in combination with standard etoposide and
cisplatin as first-line therapy for extensive-stage SCLC or neu-
roendocrine lung cancers has recently been initiated as well.
Malignant mesothelioma (MM) is known to express
elevated levels of VEGF family members and PDGFR. Pem-
etrexed with cisplatin is a standard first-line combination,
whereas no regimens have demonstrated benefit in terms of
prolonging survival in the second-line setting. Improved
therapies for MM therefore represent a clear unmet need, and
cediranib inhibits several targets known to be present in this
disease. Cediranib monotherapy is currently being evaluated
in a phase 2 trial in chemotherapy-refractory MM.
CONCLUSION
AZ2171 (cediranib) is an oral RTKI that targets VEGFRs,
PDGFR, and c-KIT, a spectrum of activity that may provide
added benefit compared with targeting VEGF alone. It also
has a broad spectrum of antitumor activity in preclinical
testing and a pharmacokinetic profile consistent with once-
daily oral dosing. It is relatively well tolerated, with the major
adverse effect being hypertension, which has been manage-
able. Early phase 1 and 2 testing suggest that the agent has
encouraging activity, including in patients with squamous
histologic findings and treated central nervous system metas-
tases. It is now being extensively investigated as monotherapy
or in combination with chemotherapy for NSCLC, SCLC, and
MM, including ongoing phase 3 testing. Results of these studies
are eagerly awaited because they will determine whether
cediranib becomes a new and much needed therapeutic option
for patients with thoracic malignancies.
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